Yuman Fong, MD

City of Hope scientists have combined two potent immunotherapies — an oncolytic virus and chimeric antigen receptor (CAR) T cell therapy — to target and eradicate solid tumors that are otherwise difficult to treat with CAR T therapy alone, according to a new Science Translational Medicine study.

In preclinical research that could lead to a clinical trial for patients with intractable solid tumors, City of Hope scientists genetically engineered an oncolytic virus to enter tumor cells and force their expression of CD19 protein on their cell surface. Scientists were then able to use CD19-directed CAR T cells to recognize and attack these solid tumors.

CD19-CAR T cell therapy is approved by the U.S. Food and Drug Administration to treat certain types of blood cancers, namely B cell lymphomas and acute lymphoblastic leukemia. This new research may expand the use of CD19-CAR T cells for the treatment of patients with potentially any solid tumor… Continue reading.

WASHINGTON, D.C.—The American Institute for Medical and Biological Engineering (AIMBE) has announced the induction of Yuman Fong, MD, Sangiacomo Chair and Chairman, Department of Surgery, City of Hope Medical Center, to its College of Fellows.

Election to the AIMBE College of Fellows is among the highest professional distinctions accorded to a medical and biological engineer. The College of Fellows is comprised of the top two percent of medical and biological engineers. College membership honors those who have made outstanding contributions to “engineering and medicine research, practice, or education” and to “the pioneering of new and developing fields of technology, making major advancements in traditional fields of medical and biological engineering, or developing/implementing innovative approaches to bioengineering education.”

Dr. Fong was nominated, reviewed, and elected by peers and members of the College of Fellows for “outstanding contributions to innovation in cancer treatment as a physician and scientist.”